Literature DB >> 9191006

Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomas.

A Matsuno1, T Sasaki, T Nagashima, R Matsuura, H Tanaka, M Hirakawa, M Murakami, T Kirino.   

Abstract

The difference in biological features between recurrent and nonrecurrent intracranial chordomas has not been studied. In this study, proliferative potentials of chordomas were studied with an immunohistochemical staining method, mainly using anti-Ki-67 antibody, MIB-1, which is known to be available for archival paraffin sections, together with immunohistochemical studies on the expression of cell cycle or apoptosis-related proteins, including p53, cyclin D1, and bcl-2 proteins. The correlation among MIB-1 staining indices, the immunoreactivities of these proteins, and clinical courses of intracranial chordomas were analyzed retrospectively, and the statistically significant correlation between MIB-1 staining index (SI) and recurrence has been clarified. The mean MIB-1 SI of recurrent tumors was 10.2%, being shown to be higher than that of nonrecurrent tumors (2.8%). The immunohistochemically positive staining of cell cycle-related protein, especially p53 and cyclin D1 proteins, correlated well with recurrence and high MIB-1 SI. In conclusion, both the examination of proliferative potentials of chordomas using MIB-1 SI and the study of the immunoreactivity of p53 and cyclin D1 proteins are important for their biological and histopathological analyses and the prediction of future recurrence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9191006     DOI: 10.1016/s0046-8177(97)90181-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

3.  Surgery for chordomas of the craniocervical junction: lessons learned.

Authors:  David Choi; Michael Gleeson
Journal:  Skull Base       Date:  2010-01

4.  Sox9/Sox6 and Sp1 are involved in the insulin-like growth factor-I-mediated upregulation of human type II collagen gene expression in articular chondrocytes.

Authors:  Emmanuelle Renard; Benoît Porée; Christos Chadjichristos; Magdalini Kypriotou; Laure Maneix; Nicolas Bigot; Florence Legendre; David Ollitrault; Benoît De Crombrugghe; Frédéric Malléin-Gérin; Safa Moslemi; Magali Demoor; Karim Boumediene; Philippe Galéra
Journal:  J Mol Med (Berl)       Date:  2012-01-04       Impact factor: 4.599

Review 5.  Apoptotic markers for primary brain tumor prognosis.

Authors:  A E Konstantinidou; P Korkolopoulou; E Patsouris
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 6.  Retroclival ecchordosis physaliphora: MR imaging and review of the literature.

Authors:  Florian Mehnert; Rudi Beschorner; Wilhelm Küker; Ulrich Hahn; Thomas Nägele
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

7.  Do All Notochordal Lesions Require Proton Beam Radiotherapy? A Proposed Reclassification of Ecchordosis Physaliphora as Benign Notochord Cell Tumor.

Authors:  Aïsha Sooltangos; Istvan Bodi; Prajwal Ghimire; Konstantinos Barkas; Sinan Al-Barazi; Nick Thomas; Eleni C Maratos
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-12

8.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

9.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

Review 10.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.